Band of Parents

23rd ANNUAL SUTTER HOME FOR HOPE CAMPAIGN DRIVES DONATIONS TO NATIONAL BREAST CANCER FOUNDATION

Retrieved on: 
Wednesday, October 18, 2023
Woman, Sale, Education, Band of Parents, Hope, Family, Sutter Home Winery, White Zinfandel, Research, Organic, Marketing, Partnership, HOPE, National Cancer Institute, Breast cancer, National Breast Cancer Foundation, Wine, National Breast Cancer Foundation (United States), Patient, QR, Birth control

ST. HELENA, Calif., Oct. 18, 2023 /PRNewswire/ -- Sutter Home Family Vineyards, a longtime champion in the fight against breast cancer, today announced the winery's renewed commitment to fighting breast cancer with the 23rd annual Sutter Home for Hope campaign. As one of America's first wine companies to make a commitment to breast cancer research, treatment and education, Sutter Home has contributed more than $1.69 million to the cause over the past 23 years. The wine brand returns in its ninth year of partnership with National Breast Cancer Foundation, Inc.® with limited-edition pink-ribbon White Zinfandel and Pink Moscato bottles in 187mL, 750mL and 1.5L formats.

Key Points: 
  • ST. HELENA, Calif., Oct. 18, 2023 /PRNewswire/ -- Sutter Home Family Vineyards , a longtime champion in the fight against breast cancer, today announced the winery's renewed commitment to fighting breast cancer with the 23rd annual Sutter Home for Hope campaign.
  • The Sutter Home for Hope initiative began in 2001, when one of Sutter Home's founding family members, Vera Trinchero Torres, was diagnosed with breast cancer.
  • For every screwcap received or QR code scanned on in-store point of sale, the winery will donate $1 to National Breast Cancer Foundation, up to $60,000.
  • With the help of Sutter Home's fans, National Breast Cancer Foundation can inspire hope to those affected by breast cancer through early detection, education and support services.

Researchers Show Lorlatinib is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk Neuroblastoma

Retrieved on: 
Monday, April 3, 2023
Army, Neoplasm, Band of Parents, Science, Discovery, MD, Patient, Disease, Children's Hospital of Philadelphia, ALK, Neuroblastoma, Emory University, St. Baldrick's Foundation, Alex's Lemonade Stand Foundation, Pediatrics, Consortium, CHOP, Wipe Out Kids' Cancer, Crizotinib, Research, Lung cancer, Pfizer, MYCN, Anaplastic lymphoma kinase, DOI, Hospital, FDA, NCI, Alvin J. Siteman Cancer Center, Safety, New Approach to Appraisal, Emory University School of Medicine, Winship Cancer Institute, Lipid, Development of the human body, COG, Children's Oncology Group, Weight gain, National Cancer Institute, International Society, Cancer, Adolescence, Band, Ronan (song), Clinical trial, Abdomen, Pharmaceutical industry, Medical imaging, Child, Nature Medicine, Parent

PHILADELPHIA, April 3, 2023 /PRNewswire/ -- In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children's Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma. The findings, published today in Nature Medicine, have led to a major amendment in a phase 3 Children's Oncology Group (COG) clinical trial, which has incorporated lorlatinib for newly diagnosed ALK-driven high-risk neuroblastoma, as well as a planned amendment to the European phase 3 trial in collaboration with the International Society of Paediatric Oncology European Neuroblastoma (SIOPEN).

Key Points: 
  • The difficulties we experienced in targeting ALK with crizotinib in neuroblastoma motivated us to find a more potent ALK inhibitor.
  • In the phase 1 NANT trial, researchers found that lorlatinib given alone or in combination with chemotherapy was safe and tolerable in pediatric, adolescent, and adult patients with relapsed/refractory ALK-driven neuroblastoma.
  • The researchers noted that younger patients treated with lorlatinib alone – particularly those with amplification of an oncogene called MYCN – had fewer responses compared to older patients.
  • "Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase I trial results," Nature Medicine, April 3, 2023, DOI: 10.1038/s41591-023-02297-5

Neuroblastoma Drugs Markets, 2019 to 2023 - Global Outlook by Product, Geography and Vendor: Key Players are Bristol-Myers Squibb, Johnson & Johnson, Pfizer, Teva Pharmaceutical, United Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 13, 2019
Health, Pharmaceutical, Cancer, Brain tumor, Neuroblastoma, RTT, Neoplasms, SWOT analysis, SWOT, Band of Parents

The neuroblastoma drugs market will register a CAGR of over 4% by 2023.

Key Points: 
  • The neuroblastoma drugs market will register a CAGR of over 4% by 2023.
  • Neuroblastoma is the most common type of childhood cancer and its incidence is gradually increasing across the world.
  • However, the rising birth rate is a major contributor to the growing incidence of neuroblastoma.
  • The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.